Long-term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy

Cancer

Volumn 92, Issue 8, 2001, Pages 2084-2094

  Puthawala, Ajmel A ^a   Nisarsyed, A M ^a   Austin, Peter A ^a   Cherlow, Joel M ^a   Perley, Jules M ^a   Shanberg, Allan M ^a   Sawyer, Donald E ^a   Ingram, John E ^b   Baghdassarian, Ruben ^a   Wachs, Barton H ^a   Perley, Jonathan E ^a   Londrc, Adina ^a   Espinoza Ferrel, Toni ^b  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brachytherapy; Iridium radioisotopes; Prostatic neoplasms; Radiotherapy

Indexed keywords

IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; IMPLANT; IMPOTENCE; LONG TERM CARE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROCTITIS; PROGNOSIS; PROSTATE ADENOCARCINOMA; RECTUM ULCER; RISK ASSESSMENT; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION; URETHRITIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; IRIDIUM RADIOISOTOPES; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS;

EID: 0035886637     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011015)92:8<2084::AID-CNCR1549>3.0.CO;2-C     Document Type: Article

References (47)

1. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer statistics 1997
2. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
3. External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States
4. Results of conservative management of clinically localized prostate cancer
5. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome
6. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increased values characterize 80% of patients
7. Prostate biopsy after definitive treatment by interstitial iodine-125 implant or external beam radiation therapy
8. Retropubic implantation of iodine-125 in the treatment of prostate carcinoma
9. High dose rate brachytherapy in the treatment of carcinoma of the prostate: Preliminary results
10. Management of prostatic cancer
11. Temporary Iridium-192 implant in the management of carcinoma of the prostate
12. Temporary implant in the management of carcinoma of the prostate
13. Transperineal percutaneous iridium-192 interstitial template implant of the prostate: Results and complications in 321 patients
14. Pelvic lymphadenectomy and transperineal interstitial implantation of Ir192 combined with external beam radiotherapy for clinically stage C prostatic carcinoma
15. Iridium-192 brachytherapy in the treatment of cancer of the prostate
16. Treatment of prostatic cancer by pelvic lymphadenectomy, temporary iridium-192 implant, and external irradiation
17. Nonparametric estimation from incomplete observations
18. Consensus statement: Guidelines for PSA following radiation therapy
19. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years
20. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: Long-term results
21. Radiation therapy for localized prostate cancer: Justification by long-term follow-up
22. Prostatic-specific antigen and external beam radiation therapy in prostatic cancer
23. Patterns of care and RTOG studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure
24. Cancer control following anatomical radical prostatectomy: An interim report
25. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy?
26. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy
27. The biological basis of endocurietherapy: The Henschke Memorial Lecture, 1984
28. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantation
29. Effect of local tumor control on distal metastasis and survival in prostatic adenocarcinoma
30. Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results of post-irradiation prostate biopsy
31. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
32. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity
33. Prostate cancer. Radiation therapy for localized disease
34. Long term outcome for men with prostate cancer treated with radiation as sole therapy
35. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate
36. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
37. Conformal external beam treatment of prostate cancer
38. Conformal proton therapy for early-stage prostate cancer
39. Recent advances in interstitial brachytherapy for localized prostate cancer
40. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer
41. Palladium-103 brachytherapy for prostate carcinoma
42. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness
43. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer
44. High dose rate afterloading iridium-192 prostate brachy-therapy: Feasibility report
45. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
46. Phase III trial of androgen suppression using goserlin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31